<p>在谷歌搜索和人工智能答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开谷歌</p>
<p>在谷歌上添加</p>
<p>圣地亚哥，2026 年 6 月 1 日（全球新闻通讯社）—— Zentalis® Pharmaceuticals, Inc.（纳斯达克：ZNTL），一家临床肿瘤学创新公司，正在推进其首个 WEE1 抑制剂 azenosertib 的晚期开发，作为卵巢癌的生物标志物驱动治疗方法，今天宣布在 2026 年 6 月 1 日，Zentalis 董事会的薪酬委员会向两名新聘员工授予了总计 191,000 股公司普通股的非合格股票期权。这些股票期权是根据 Zentalis Pharmaceuticals, Inc. 2022 年就业诱导激励奖励计划（2022 诱导计划）授予的，作为每位个人进入 Zentalis 工作的诱因，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>2022 诱导计划专门用于向之前不是 Zentalis 员工的个人授予股权奖励，或在经过真实的非就业期后，作为每位个人进入 Zentalis 工作的诱因，依据纳斯达克上市规则 5635(c)(4)。</p>
<p>股票期权的行使价格为每股 3.98 美元，等于授予日 Zentalis 普通股在纳斯达克全球市场的收盘价。股票期权的有效期为 10 年，并将在四年内逐步归属，其中 25% 的期权将在归属开始日期的第一周年时归属，其余 75% 的期权将在接下来的三年内按月均匀归属。</p>
<p>股票期权的归属取决于员工在每个归属日期继续为 Zentalis 服务。</p>
<p><strong>关于 Zentalis Pharmaceuticals</strong></p>
<p>Zentalis 是一家临床肿瘤学创新公司，开发卵巢癌和多种肿瘤类型的治疗方法。Zentalis 利用治疗开发和生物标志物的专业知识，推进其首个 WEE1 抑制剂 azenosertib 的单药和联合研究。我们专注于将 WEE1 科学转化为临床实践，旨在为医生提供一种靶向、非化疗、可口服的药物，以提升治疗体验、选择和结果。我们的使命：为癌症患者提供更便捷和关怀的服务。</p>
<p>欲了解更多信息，请访问 www.zentalis.com。在 LinkedIn 上关注 Zentalis，网址为 www.linkedin.com/company/zentalis-pharmaceuticals。</p>
<p><em>ZENTALIS</em> <em>®</em> <em>及其相关标志是 Zentalis 及/或其附属公司的商标。本新闻稿中的所有网站地址和其他链接仅供参考，并不打算作为活动链接或将任何网站或其他信息纳入本新闻稿。</em></p>
<p><strong>联系方式：</strong></p>
<p>Aron Feingold</p>
<p>投资者关系与企业传播副总裁</p>
<p>ir@zentalis.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek1EQXhNeU0zTmpNeE16VXhJekl4T1RRM05ETT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek1EQXhNeU0zTmpNeE16VXhJekl4T1RRM05ETT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODJkMjI5M2ItZmY2Ny00ZThlLWE0ZjgtZTNhM2IwNWFmZWU2LTEyMDYyOTYtMjAyNi0wNi0wMS1lbg==/tiny/ZENTALIS-PHARMACEUTICALS.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODJkMjI5M2ItZmY2Ny00ZThlLWE0ZjgtZTNhM2IwNWFmZWU2LTEyMDYyOTYtMjAyNi0wNi0wMS1lbg==/tiny/ZENTALIS-PHARMACEUTICALS.png"/></p>

ZNTL

<p>Zentalis Pharmaceuticals 宣布根据纳斯达克上市规则 5635(c)(4) 进行激励授予。2026 年 6 月 1 日，薪酬委员会向两名新聘员工授予了 191,000 股非合格股票期权。行使价格为每股 3.98 美元，与授予日的收盘价相符。期权的有效期为 10 年，并在四年内逐步归属，前提是持续服务</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在谷歌搜索和人工智能答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开谷歌</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在谷歌上添加</p>
</div><p>SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on June 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 191,000 shares of the Company’s common stock to two (2) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>圣地亚哥，2026 年 6 月 1 日（全球新闻通讯社）—— Zentalis® Pharmaceuticals, Inc.（纳斯达克：ZNTL），一家临床肿瘤学创新公司，正在推进其首个 WEE1 抑制剂 azenosertib 的晚期开发，作为卵巢癌的生物标志物驱动治疗方法，今天宣布在 2026 年 6 月 1 日，Zentalis 董事会的薪酬委员会向两名新聘员工授予了总计 191,000 股公司普通股的非合格股票期权。这些股票期权是根据 Zentalis Pharmaceuticals, Inc. 2022 年就业诱导激励奖励计划（2022 诱导计划）授予的，作为每位个人进入 Zentalis 工作的诱因，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>2022 诱导计划专门用于向之前不是 Zentalis 员工的个人授予股权奖励，或在经过真实的非就业期后，作为每位个人进入 Zentalis 工作的诱因，依据纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The stock options have an exercise price of $3.98 per share, which is equal to the closing price of Zentalis’ common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter.</p>
<div class="lb-trans"><p>股票期权的行使价格为每股 3.98 美元，等于授予日 Zentalis 普通股在纳斯达克全球市场的收盘价。股票期权的有效期为 10 年，并将在四年内逐步归属，其中 25% 的期权将在归属开始日期的第一周年时归属，其余 75% 的期权将在接下来的三年内按月均匀归属。</p>
</div><p>Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.</p>
<div class="lb-trans"><p>股票期权的归属取决于员工在每个归属日期继续为 Zentalis 服务。</p>
</div><p><strong>About Zentalis Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>关于 Zentalis Pharmaceuticals</strong></p>
</div><p>Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.​</p>
<div class="lb-trans"><p>Zentalis 是一家临床肿瘤学创新公司，开发卵巢癌和多种肿瘤类型的治疗方法。Zentalis 利用治疗开发和生物标志物的专业知识，推进其首个 WEE1 抑制剂 azenosertib 的单药和联合研究。我们专注于将 WEE1 科学转化为临床实践，旨在为医生提供一种靶向、非化疗、可口服的药物，以提升治疗体验、选择和结果。我们的使命：为癌症患者提供更便捷和关怀的服务。</p>
</div><p>For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.zentalis.com。在 LinkedIn 上关注 Zentalis，网址为 www.linkedin.com/company/zentalis-pharmaceuticals。</p>
</div><p><em>ZENTALIS</em> <em>®</em> <em>and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.</em></p>
<div class="lb-trans"><p><em>ZENTALIS</em> <em>®</em> <em>及其相关标志是 Zentalis 及/或其附属公司的商标。本新闻稿中的所有网站地址和其他链接仅供参考，并不打算作为活动链接或将任何网站或其他信息纳入本新闻稿。</em></p>
</div><p><strong>Contact:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>Aron Feingold</p>
<div class="lb-trans"><p>Aron Feingold</p>
</div><p>VP, Investor Relations &amp; Corporate Communications</p>
<div class="lb-trans"><p>投资者关系与企业传播副总裁</p>
</div><p>ir@zentalis.com</p>
<div class="lb-trans"><p>ir@zentalis.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1Rjek1EQXhNeU0zTmpNeE16VXhJekl4T1RRM05ETT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTczMDAxMyM3NjMxMzUxIzIxOTQ3NDM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODJkMjI5M2ItZmY2Ny00ZThlLWE0ZjgtZTNhM2IwNWFmZWU2LTEyMDYyOTYtMjAyNi0wNi0wMS1lbg==/tiny/ZENTALIS-PHARMACEUTICALS.png" alt="" original-src="https://ml.globenewswire.com/media/ODJkMjI5M2ItZmY2Ny00ZThlLWE0ZjgtZTNhM2IwNWFmZWU2LTEyMDYyOTYtMjAyNi0wNi0wMS1lbg==/tiny/ZENTALIS-PHARMACEUTICALS.png"/></p>

Zentalis Pharmaceuticals 宣布根据纳斯达克上市规则 5635(c)(4) 授予诱导性股票奖励 | ZNTL 股票新闻